Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
复制标题
DOI：
10.1016/s0090-4295(96)00381-0
复制
发表时间：
1996-11-01
期刊：
影响因子：
2.1
通讯作者：
Lange, PH
中科院分区：
文献类型：
--
作者：
Higano, CS;Ellis, W;Lange, PH
目标.目的：探讨间歇性雄激素抑制治疗初治前列腺癌的可行性。亮丙瑞林和氟替卡松给药9 - 12个月，然后停药，直至前列腺特异性抗原（PSA）水平达到由基线PSA值确定的阈值。这构成了一个治疗周期。雄激素抑制，然后间歇地给予描述，直到有雄激素依赖的证据。22例PSA治疗失败的患者接受了手术和/或放疗的初步治疗，以及未经治疗的早期或D2期疾病。21例患者在第1周期完成了雄激素抑制治疗，至PSA最低值的中位时间为3.5个月（范围，2至12个月）。15例患者完成了第1周期，中位停药时间为6个月（范围，2 - 19）或38%（范围，17%-64%）的治疗周期。6例患者在周期I期间继续停止治疗，持续时间为I +至31 +个月。在第2周期，12例患者在中位时间3.5个月内达到PSA最低值。2例患者完成了第2周期，中位停药时间为10个月（51%），所有患者的中位随访时间为26个月（范围，10 - 51）。停止治疗后，所有患者均报告雄激素抑制相关症状减轻。间歇性雄激素抑制是治疗前列腺癌的持续雄激素抑制的可行替代方案，并且在停止治疗时改善了生活的双重性。版权所有1996年由爱思唯尔科学公司。
Objectives. To affirm the feasibility of using intermittent androgen suppression in patients with hormone-naive prostate cancer.Methods. Leuprolide and flutamide were administered for 9 to 12 months and then discontinued until prostate-specific antigen (PSA) levels reached a threshold value determined by the baseline PSA value. This constituted one cycle of treatment. Androgen suppression was then administered intermittently as described until there was evidence of androgen independence.Results. Twenty-two patients with PSA failure after primary therapy with surgery and/or radiation and untreated early or Stage D2 disease were treated. Twenty-one patients completed androgen suppression during cycle 1, with a median time to PSA nadir of 3.5 months (range, 2 to 12). Fifteen patients completed cycle 1 with a median time off treatment of 6 months (range, 2 to 19) or 38% (range, 17% to 64%) of a treatment cycle. Six patients continued off treatment during cycle I for I + to 31 + months. During cycle 2, 1 2 patients achieved a PSA nadir in a median time of 3.5 months. Two patients completed cycle 2 with a median time off treatment of 10 months (51%), Median follow-up for all patients is 26 months (range, 10 to 51). While off treatment, all patients reported a reduction of symptoms associated with androgen suppression.Conclusions. Intermittent androgen suppression is a feasible alternative to continuous androgen suppression for treatment of prostate cancer, and duality of life is improved while off treatment. Copyright 1996 by Elsevier Science Inc.